	US 12,304,958 B2
	Antibodies targeting ActRIIA and ActRIIB
Christian Kunz, Basel (CH); Amélie Wiederkehr, Ranspach le bas (FR); Lisa Wellinger, Basel (CH); Anne Laure Lainé, Huningue (FR); Emily Radke, West Lebanon, NH (US); Caitlin Stein, Clarkston, MI (US); and Arvind Sivasubramanian, Santa Clara, CA (US)
Assigned to Six Peaks Bio AG, Basel (CH)
Filed by SixPeaks Bio AG, Basel (CH)
Filed on Nov. 13, 2024, as Appl. No. 18/945,784.
Application 18/945,784 is a continuation of application No. 18/898,854, filed on Sep. 27, 2024, abandoned.
Claims priority of application No. 23200478 (EP), filed on Sep. 28, 2023.
Prior Publication US 2025/0109208 A1, Apr. 3, 2025
Int. Cl. C07K 16/28 (2006.01)

CPC C07K 16/2863 (2013.01) [C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01)]

14 Claims

1. An antibody or antigen binding fragment thereof which binds to Activin receptor II A (ActRIIA) and/or Activin receptor II B (ActRIIB) comprising:

a) a heavy chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 3;

b) a heavy chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 11;

c) a heavy chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 5;

d) a light chain variable region CDR1 comprising the amino acid sequence of SEQ ID NO: 22;

e) a light chain variable region CDR2 comprising the amino acid sequence of SEQ ID NO: 13 and

f) a light chain variable region CDR3 comprising the amino acid sequence of SEQ ID NO: 14.